Arbutus Biopharma Investor Relations Material
Latest events
Status Update
Arbutus Biopharma
Q1 2025
14 May, 2025
Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arbutus Biopharma Corporation
Access all reports
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for viral diseases. The company utilizes its expertise in RNA interference (RNAi) technology and small molecule development to address diseases such as chronic hepatitis B. Arbutus conducts research and development to advance its proprietary drug candidates and explore combination treatment approaches. The company is headquartered in Warminster, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ABUS
Country
🇺🇸 United States